Sorafenib Induced Hand and Foot Syndrome
نویسندگان
چکیده
منابع مشابه
Pazopanib induced hand-foot syndrome
A 55-year-old male was diagnosed as a case of metastatic renal cell carcinoma (clear cell histology) and started on tyrosine kinase inhibitor (TKI) pazopanib. He reported back to us 2 weeks later with painful, erythematous and desquamating lesions of the hands and soles. On examination, erythematous and desquamating lesion involving dorsum of hands and soles consistent with grade 2 hand-foot sy...
متن کاملSorafenib-asssociated hand-foot syndrome treated with topical calcipotriol
INTRODUCTION Sorafenib is a multitargeted potent antiangiogenic tyrosine kinase inhibitor. Sorafenib has antiproliferative and antineoplastic effects in addition to antiangiogenic effects. According to research, the use of sorafenib is effective in the treatment of advanced hepatocellular carcinoma. However, sorafenib has several side effects including hand-foot skin reaction, alopecia, and Ste...
متن کاملGrade III hand-foot skin reaction induced by sorafenib*
1 Department of Dermatology, Apollonia University – Iasi, Romania. 2 Department of Dermatology, Institute of Macromolecular Chemistry “Petru Poni” – Iasi, Romania. 3 Department of Dermatology, Nicolina Medical Center – Iasi, Romania 4 Department of Surgery, University of Medicine and Pharmacy of Targu Mures – Mures, Romania. 5 Department of Cardiology, University of Medicine and Pharmacy of Tar...
متن کاملManagement of Paclitaxel-induced hand-foot syndrome.
BACKGROUND Hand-foot syndrome (HFS), also known as acral erythema or palmoplantar dysesthesia, is a manifestation of painful erythema and dysesthesia mostly occurring in the palms and soles. Although many chemotherapeutic agents have been shown to cause HFS, it remains an uncommon adverse cutaneous manifestation of paclitaxel. CASE REPORT We report a case of paclitaxel-induced grade 3 HFS in ...
متن کاملSorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.
Sorafenib (Nexavar®, BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has recently been approved for the treatment of metastatic renal cell carcinoma. It is also used to delay disease progression in patients with advanced solid organ malignancies and metastatic melanoma. Sorafenib is associated with a relatively high incidence of dermatologic adverse events. The commonly...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Young Pharmacists
سال: 2018
ISSN: 0975-1483,0975-1505
DOI: 10.5530/jyp.2018.10.29